Vest Financial LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,638,279 shares of the company's stock after buying an additional 167,265 shares during the quarter. Kenvue accounts for about 1.0% of Vest Financial LLC's investment portfolio, making the stock its 18th largest position. Vest Financial LLC owned approximately 0.14% of Kenvue worth $63,266,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC boosted its holdings in Kenvue by 29.8% in the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock worth $1,736,000 after purchasing an additional 18,650 shares in the last quarter. Spire Wealth Management bought a new stake in Kenvue during the fourth quarter worth about $95,000. U.S. Capital Wealth Advisors LLC grew its stake in shares of Kenvue by 5.6% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 29,298 shares of the company's stock valued at $626,000 after purchasing an additional 1,551 shares during the last quarter. Mather Group LLC. grew its stake in shares of Kenvue by 55.0% during the fourth quarter. Mather Group LLC. now owns 10,627 shares of the company's stock valued at $227,000 after purchasing an additional 3,770 shares during the last quarter. Finally, Stratos Wealth Partners LTD. grew its holdings in Kenvue by 4.7% during the 4th quarter. Stratos Wealth Partners LTD. now owns 13,461 shares of the company's stock worth $287,000 after acquiring an additional 601 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Barclays upped their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Finally, Canaccord Genuity Group raised their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $25.33.
Check Out Our Latest Research Report on Kenvue
Kenvue Trading Up 0.4%
Kenvue stock traded up $0.08 during midday trading on Friday, reaching $21.73. 9,670,463 shares of the stock traded hands, compared to its average volume of 16,361,790. The company has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $22.60. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $41.69 billion, a PE ratio of 41.00, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17.
Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue's quarterly revenue was down 3.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.28 earnings per share. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.77%. Kenvue's payout ratio is currently 149.09%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
